Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Instituto Valenciano de Oncologı´a, Valencia, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:4City/State/Province:Valencia
Treatments:ChemotherapyHospital:Instituto Valenciano de Oncologı´a
Drugs:Journal:Link
Date:Jan 2011

Description:

Patients:
This study involved ovarian cancer patients with partially platinum-sensitive relapse after previous platinum-based therapy. Patients were divided into two separate treatment groups. Group A consisted of 91 patients with a median age of 56 years. Group B had 123 patients with a median age of 57 years.

Treatment:
Group A was treated with the chemotherapy agent pegylated liposomal doxorubicin (PLD). Group B was treated with the chemotherapy agents PLD and trabectedin.

Toxicities:
Maximum toxicity grade was 4 for both treatment groups. In group A, toxicities included 9 cases of grade 4 neutropenia and 17 cases of grade 3 hand-foot syndrome. Group B reported 39 cases of grade 4 neutropenia and 9 cases of grade 4 thrombocytopenia.

Results:
The reported median overall survival was 17.1 months for group A and 23.0 months for group B.

Support:
This study was supported by Johnson & Johnson, the makers of trabectedin.

Correspondence: Dr A. Poveda; email: [email protected]



Back